April 10, 2026

Where Oversight, Compliance, and Risk Intersect

Cases spanning fraud, regulation, and criminal law illustrate how gaps and uncertainty can influence outcomes in healthcare settings

Conexiant

April 09, 2026

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.

Conexiant

April 08, 2026

Forensic Dermatology and the CSI Effect

Media portrayals of forensic skin evidence create unrealistic jury expectations—and dermatologists testifying in court may need strategies to address them

Conexiant

April 06, 2026

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Conexiant

April 06, 2026

UVB and Psoriasis: More Than Immunosuppression

UVB's benefits may run deeper than inflammation suppression—cholesterol metabolism could be a key link.

Conexiant

April 06, 2026

HS Linked to Higher Cancer Risk

Investigators report site-specific cancer associations and limited adjusted estimates in meta-analysis.

Conexiant

April 03, 2026

Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies

Conexiant

April 01, 2026

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

Conexiant

April 01, 2026

Predicting Recurrence in Early Melanoma

Study identifies tumor features beyond staging that predict recurrence risk in early disease

Conexiant

March 30, 2026

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Conexiant